MAP Patient Access Limited

Exciting News: The MAP Group expands its European market access expertise with SKC acquisition We are pleased to announce that The MAP Group has made a significant advancement in fortifying our presence across Europe by acquiring SKC Beratungsgesellschaft mbH, a preeminent German consultancy in market access, pricing, and reimbursement. This acquisition allows us to expand our team, enhance our expertise, and increase our footprint in one of Europe’s most vital markets. SKC, established in 2005 and headquartered in Hannover, Germany, brings invaluable experience and insight, aiding companies in the pharma, biotech, medtech, and digital health sectors with intricate strategic matters.   Steve Glass, CEO of The MAP Group, expressed enthusiasm regarding the acquisition: “With the integration of the seasoned and skilled team from SKC, we further our mission to ensure patient access to transformative therapies in Europe and beyond. As the implications of the imminent EU-HTA loom, this acquisition represents a critical step in expanding our pan-European presence and supporting our clients in a constantly evolving landscape, with a global perspective and essential local expertise.”   We eagerly anticipate collaborating to achieve even greater success for our clients, making a significant impact on healthcare across Europe! Read the full press release here: https://lnkd.in/evRnpEmd #growth #patientaccess #marketaccess #europe #team

New blog: living systematic reviews (LSRs) In our latest blog, Jessica Radford takes a look at LSRs and their ability to adapt to the constant influx of new information, making them an essential tool for modern research and decision-making.  Contact us to learn how we can support your organisation with our LSR services, ensuring you always have access to the most relevant and current evidence. Read more here: https://lnkd.in/eCUYJYgu #SLR #LSR #HTA #marketaccess #patientaccess #literaturereview 

Are you interested in keeping up to date on Health Technology Assessment (HTA) activity in the UK and Ireland? If so, why not sign up to receive our monthly HTA overview? Each month, we compile the latest updates on UK and Ireland HTAs, offering a clear overview of products in the process. Newsletter subscribers receive monthly highlights, while our valued members enjoy exclusive access to a detailed monthly report featuring data from various HTA organisations and individual products. If you'd like to receive November's report, sign up now: https://lnkd.in/eW4Sghku #healthtechnology #HTA #SubscribeNow

MAP Group: your partner for patient access in Europe   We are committed to breaking down barriers to patient access across Europe. With our expertise spanning over 20 European markets, we are the trusted partner to navigate the complexities of regulatory landscapes, market incentives, and pricing strategies in the UK and Europe.   With Europe’s rapidly changing incentives and evolving regulations for innovative therapies, having a strategic plan in place from the outset is crucial. Partner with us to make your journey smoother—from regulatory pathways to successful patient access.   #Europe #PatientAccess #MarketAccess

If you are looking to deepen your understanding of the new EU HTA framework or have any questions around its implications, take a look at the upcoming Q&A session with our colleagues at SKC Beratungsgesellschaft mbH. This is a great opportunity to ask EU HTA experts and market access professionals all burning questions related to EU HTA.    The session takes place virtually on 10 December at 3.30pm CET. Secure your free place below:

2025 will mark the 20th anniversary of the Small and Medium Enterprise (SME) regulation, and the European Medicines Agency (EMA) continues to recognise SMEs as important actors in innovation and the development of new medicinal products. Incentives are provided to help SMEs overcome some of the financial and administrative hurdles associated with bringing a product to market. Our team understand the difficulties that can be faced by SMEs when developing innovative products and can provide solutions customised to your stage of development. Read on to find out more: https://lnkd.in/e_5PVi7x #RegulatoryAffairs #SMEs #EMA

Are you ready to launch your product in the UK? Our resource is ready to guide you through the entire process! With deep expertise in market access and UK HTA submissions, we can help you craft a strategy for launch success. Grab our essential 12-point checklist here: https://lnkd.in/ezviuJpu #UKMAChecklist #UK #HealthTechnology

Congratulations to Kristof Theys, PhD for being selected as an expert tutor for a course on statistics for medical affairs for CELforPharma! CELforPharma are a well-known teaching institute who work with thought leaders and industry experts to provide courses covering the (Bio)Pharma & Medtech sectors.    Kristof’s course is called “Essentials of Statistical Thinking for Medical Affairs – How to Effectively Interpret and Translate the Statistics of Medical Studies & Scientific Publications”. What a great achievement Kristof!   To find out more about the course, visit: https://lnkd.in/eqDAX_5K   #CELforPharma #Expertise #TeamSpotlight

As the European Union moves towards a more unified approach to national bodies in the member states, the EU Health Technology Assessment (HTA) Regulation will start to apply from January 2025. If you are planning to launch an asset under the new EU HTA Regulations, you will need to prepare your HTA dossiers earlier than before and be aware that these may be more complex in nature. Your Joint Clinical Assessment (JCA) dossier should cover all consolidated PICOs identified by the member states, so you need to be aware that the evidence generation requirements have increased.  Find out more about our recommendations in our recent blog: https://lnkd.in/eRX3JcQt #EUHTA #PICOScoping #Europe #JointClinicalAssessment